Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arresto BioSciences Inc.

Division of Gilead Sciences Inc.
www.arresto.com

Latest From Arresto BioSciences Inc.

Gilead Pays Phenex $100m Milestone As NASH Candidate Progresses

With hepatitis C wrapped up, NASH is becoming the focus of liver disease R&D. Gilead, which has a number of NASH programs, has paid Phenex $100m for clinical progress with an in-licensed candidate for NASH and other liver diseases.

Commercial Deals

After Pirfenidone: Broad Competition To Bring First Therapy For Underlying Cause Of IPF To Market

In the latest in “The Pink Sheet”’s market snapshot series, InterMune continues to work on getting pirfenidone approved in the U.S., while several companies are developing next-stage therapies for IPF.

BioPharmaceutical North America

$21.5 Million Series D Round Gives Promedior Runway To Advance Lead Program In Two Fibrotic Indications

Recent deal-making has brought larger, deeper-pocketed players into the IPF space, but Promedior still likes its approach of going it alone with Pentraxin-2-based therapies in fibrotic disease.

BioPharmaceutical Medical Device

Deals Of The Week: Valeant/Eyetech, Merck/Supera Farma, Merck/Zhifei

Biogen’s purchase of Stromedix completes the buy-up of independently held biotech assets in the furious competition to take the lead in idiopathic pulmonary fibrosis.

BioPharmaceutical Asia Pacific
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Hepatic (Liver)
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Gilead Sciences Inc.
  • Senior Management
  • Peter Van Vlasselaer, PhD, Pres. & CEO
    Victoria Smith, PhD, VP, R&D
  • Contact Info
  • Arresto BioSciences Inc.
    Phone: (650) 352-5564
    3183 Porter Dr.
    Palo Alto, CA 94304
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register